This content is machine translated Psoriasis treatment with biologics What are the latest trends? Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data...…
View Post 8 min This content is machine translated Psoriasis The era of biologics – a tour d’horizon through significant research decades The development of highly effective biologics was preceded by research efforts over several decades. Advances in immunopathogenetic and molecular genetic analyses contributed significantly to the generation of these innovative system…
View Post 5 min This content is machine translated Psoriasis: "Awareness" of comorbidities Cardiometabolic diseases and other comorbidities In addition to certain risk and trigger factors, psoriasis is associated with various comorbidities, such as metabolic syndrome, cardiovascular disease, and depression. This is particularly true for patients with moderate…
View Post 3 min This content is machine translated Guselkumab in psoriatic arthritis Early response predicted Recent analyses of a heterogeneous group of patients with active psoriatic arthritis (PsA) show that early treatment response with respect to skin psoriasis and enthesitis is a predictor of sustained…
View Post 5 min This content is machine translated AAD 2018, San Diego From rare and common skin conditions Psoriasis therapy has been significantly expanded in recent years. New substances are continuously entering the market. Merkel cell carcinoma, on the other hand, is a rare skin tumor with a…
View Post 5 min This content is machine translated Moderate to severe psoriasis Safety and efficacy of PDE4 inhibition. Psoriasis is a skin disease caused by a disorder of the immune system with subsequent strong cell growth. It can be divided into different forms: Plaque Psoriasis (Psoriasis vulgaris), Psoriasis guttata,…
